Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Qiaosheng Xie"'
Autor:
Meng Wei, Yunhai Mo, Jialong Liu, Jingtong Zhai, Huilong Li, Yixin Xu, Yumeng Peng, Zhihong Tang, Tao Wei, Xiaopan Yang, Linfei Huang, Xiao Shao, Jingfei Li, Li Zhou, Hui Zhong, Congwen Wei, Qiaosheng Xie, Min Min, Feixiang Wu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
As a critical immune checkpoint molecule, PD-L1 is expressed at significantly higher levels in multiple neoplastic tissues compared to normal ones. PD-L1/PD-1 axis is a critical target for tumor immunotherapy, blocking the PD-L1/PD-1 axis is recogniz
Externí odkaz:
https://doaj.org/article/48ae264efab242bbb6893345aab19443
Publikováno v:
Resources Policy. 76:102716
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf63c0e6d7b537e92ecb3747f1a10fa5
https://doi.org/10.1016/j.resourpol.2022.102716
https://doi.org/10.1016/j.resourpol.2022.102716
Publikováno v:
Cancer Biology & Therapy. 19:198-204
Sarcomas are rare but malignant tumors with high risks of local recurrence and distant metastasis. Anti-angiogenic therapy is a potential strategy against un-controlled and not-organized tumor angiogenesis. We aimed to assess the safety and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc6c27cd10ff2db4be23b8a1db093c01
https://doi.org/10.1080/15384047.2017.1416275
https://doi.org/10.1080/15384047.2017.1416275
Autor:
Baile Zuo, Angang Yang, Lei Wang, Shengli Zhang, Lin-Tao Jia, Zhiwei Yang, Qiaosheng Xie, Guoyin Li, Xiang Zhang
Publikováno v:
International journal of cancerReferences. 145(12)
Human epidermal growth factor receptor 2 (HER2/erbB2) is a key driver and therapeutic target for breast cancer. The treatment of HER2-positive breast cancer remains a clinical challenge largely due to the limited understanding of HER2-driving oncogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::296fdb9343c1082e68de1ae2957747f3
https://pubmed.ncbi.nlm.nih.gov/31111958
https://pubmed.ncbi.nlm.nih.gov/31111958
Publikováno v:
Journal of Clinical Oncology. 35:e22502-e22502
e22502 Background: Soft tissue sarcomas (STSs) are rare but malignant tumors with high risks of local recurrence and distant metastasis. Promising efficacy of apatinib was reported in several subtypes of STSs (Dong et al. 2016, Medicine 95: e4368; Ji
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b7762f2a17e492d43b3ea31f9719e62
https://doi.org/10.1200/jco.2017.35.15_suppl.e22502
https://doi.org/10.1200/jco.2017.35.15_suppl.e22502